Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
9.76
-0.12 (-1.21%)
Dec 1, 2025, 4:00 PM EST - Market closed
Anika Therapeutics Revenue
Anika Therapeutics had revenue of $27.82M in the quarter ending September 30, 2025, a decrease of -5.89%. This brings the company's revenue in the last twelve months to $112.81M, up 30.55% year-over-year. In the year 2024, Anika Therapeutics had annual revenue of $119.91M, down -0.73%.
Revenue (ttm)
$112.81M
Revenue Growth
+30.55%
P/S Ratio
1.25
Revenue / Employee
$391,688
Employees
288
Market Cap
140.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.91M | -885.00K | -0.73% |
| Dec 31, 2023 | 120.79M | 6.97M | 6.12% |
| Dec 31, 2022 | 113.83M | -33.97M | -22.98% |
| Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
| Dec 31, 2020 | 130.46M | 15.85M | 13.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ANIK News
- 26 days ago - Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Anika Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025 - GlobeNewsWire
- 7 weeks ago - ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders - GlobeNewsWire
- 3 months ago - Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts - Seeking Alpha
- 4 months ago - Anika (ANIK) Q2 Revenue Beats by 4% - The Motley Fool
- 4 months ago - Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript - Seeking Alpha